Method for treating the cases of leukopenia

FIELD: medicine.

SUBSTANCE: method involves administering inmmunotherapy with recombinant interferon-α2b in daily dose of 3x106 MU. It is incubated in thermostat during 1 h at 37°C with 100 ml of autoblood and then it is intravenously introduced to a patient during 1-1.5h daily under blood formula control to reach leukocyte content of>4*109 /l, granulocytes >2*109 /l.

EFFECT: eliminated leukopenia and dose-limiting toxicity risk; accelerated treatment course; reduced risk of infectious complications.

 

The invention relates to medicine, namely to Oncology, and can be used in the treatment of radiation in cancer patients.

There is a method of treatment of leukopenia after chemotherapy of cancer patients (see Mlechanovci. Complications of chemotherapy and hormonal therapy of malignant tumors. M.: Medicine, 1982, p.120).

How is that to emotially used glucocorticoids, in particular prednisolone at moderate doses of 15-25 mg per day.

However, the use of corticosteroids is accompanied lymphopoesis effect has ulcerogenic and hypertensive effect, causes the syndrome Itsenko-Cushing syndrome, hypokalemia, immunosuppression, the syndrome that really complicates the treatment process, is not efficient enough.

Known "Method of treatment of non-Hodgkin lymphoma (see patent No. 2180594 from 20.03.02, publ. Bulletin No. 28), we have chosen as a prototype. How is that taking autochrome in the amount of 250 ml, and 150 ml incubated with anti-tumor drugs, 100 ml Intron a dose of 15×106ME, both mixtures are placed in separate vials in a thermostat at a temperature of 37°With exposure time of 1 hour, and then intravenously injected to the patient a mixture of blood with anticancer drugs for 25-30 minutes and the mixture of blood with intron a for 2-3 hours prior the second premedication, the procedure is repeated on the 8th day, a total of 6 courses of treatment.

The effectiveness of the method consists in the elimination of tumor cells in circulating blood and organs, reduction of tumor size and lymph node.

The known method has drawbacks: treatment intron a in large doses up to 15×106ME accompanied by hyperthermia to 38-39°and the necessity of application of paracetamol before and after Intron A; leukopenia, which does not allow him to apply to emotially.

The aim of the invention is the treatment of leukopenia in patients with cancer of various localizations common stages of the malignant process.

This goal is achieved by the fact that patients with leukopenia carry out the treatment with recombinant interferon-α2b in a daily dose of 3×106ME, which is incubated in the incubator for 1 hour at a temperature of 37°With 100 ml of autologous blood and then injected intravenously to the patient during 1-1,5 hours per day, under the control of the blood, to normalize blood content > 4×109/l, granulocytes > 2×109/HP

The invention of "a Method for the treatment of leukopenia is new, as it is unknown the level of medicine in the treatment of radiation - complications of chemotherapy for cancer patients.

The novelty of the invention lies in the fact that cancer patients who hypoxia locations with extensive tumor process in the development of radiation to the II-III degree and unable to continue the chemotherapy are autogemoterapii with recombinant interferon-α 2b at a dose of 3×106ME with 100 ml of autologous blood and achieving normal blood content > 4×109/l and granulocytes > 2×109/l on average up to 3 days.

In contrast to the known method of cancer treatment of non-Hodgkin lymphoma intron a dose of 15×106ME in the prototype, in our treatment, the radiation quantity of the blood is reduced 2.5 times, and a single dose of Intron And 5 times. Interferon-α2b is contraindicated for use in radiation. However, in our proposed method, it is less than 5 times, with the use of autologous blood allows you to get gemostimuliruyuschee effect.

Respectively, and decrease side effects: pyrexia, influenza-like syndrome, anorexia, hepatotoxic effects. In addition, the drug has anti-tumor activity, immunotherapy effect, which is important when treating cancer patients with radiation.

The invention of "a Method for the treatment of leukopenia is industrially applicable, as may be used in health care, in medical institutions chemotherapy for patients with malignant tumors of various localizations, with a common process, accompanied by radiation, cancer institutes, oncological dispensaries.

"Treatment of radiation" is SL is blowing this:

Patients with grade II-III degree within 3 days, daily, administered interferon-α2b 3×106ME, incubated in autologous blood in quantities of 100 ml in thermostat for about 1 hour at a temperature of 37°C. Then the mixture is injected, drip for 1-1 .5 hours under the control of the blood. When reaching the number of leukocytes > 4×109/l and granulocytes > 2×109/l treatment ceased.

The specific examples of the application of the treatment radiation".

1. Zenin HE, born in 1977, case history No. 5958/W.

Diagnosis: Hodgkin's disease (lymphoid depletion), stage II B source, with lesions of the cervical, axillary lymph nodes on both sides, mediastinal lymph nodes. Activation with the defeat of the retroperitoneal lymph nodes. Condition after chemoradiation treatment.

Upon receipt 04.12.2002 year in the General analysis of blood leukocytes to 1.9×109/l: p 12%, 61%, m 9%l 18%, granulocytes 1,3×109/HP

Patients leukopenia III, granulocytopenia II degree.

04-06.12.2002 introduced intravenously for 1-1,5 hours on 3×106ME Intron And incubated with 100 ml of autologous blood in a thermostat at a temperature of 37°C for 1 hour.

General blood tests after treatment 07.12.2002 year: leukocytes 4,2×109/l, p 12%, 48%, m 17%l 23%, the number of granulocytes 2,5 on; 109/HP

After treatment is normalization of the number of leukocytes and granulocytes, which allowed us to continue chemotherapy.

2. Soloduhina L.N., born in 1947, case history No. 6083/O.

Diagnosis: Cancer of the right breast (IX 02 - ablation with LAE - T4N2M1with lesions of the soft tissues of the anterior chest wall. Clinical group 4.

General analysis of blood from 19.11.02: leukocytes 2,9×109/l, p 3%, with 60%e 1%, m 5%l 31%, granulocytes 1,8×109/L. the patient leukopenia, grade II granulocytopenia I class.

From 19 to 21.11.02 was introduced intron And by the proposed method.

General blood tests after treatment 21.11.02: leukocytes 4,7×109/l, p 11%, with 32%e 6%, 19%, l 31%, granulocytes 2×109/HP

Chemotherapy was continued.

3. Alisultanov M.A., 1963 year of birth, medical history, No. 8359/O.

Diagnosis: Cancer of the left breast (ITRS X 02 - T3N1M0). Clinical group 3.

General analysis of blood from 23.12.02: leukocytes 2,5×109/l, p 7%, 48%, m 11%l 34%, granulocytes 1,3×109/L. the patient leukopenia II degree, penulimate II degree.

24 26.12.02. introduced intron And autologous blood by the proposed method.

General analysis of blood after treatment 27.12.02: leukocytes 4,1×109/l, p 14%, 60%, m 2%l 24%, granulocytes 3×109/HP

There is normalization of blood counts, when the eat the increase in the number of granulocytes in more than 2 times.

The patient continued chemotherapy.

Technical and economic efficiency "treatment of radiation" is that it helps to overcome the dose-limiting toxicity of chemotherapy-radiation for a short period of time, to intensify and to carry out the treatment of cancer patients. In patients with reduced infectious complications of febrile neutropenia, stimulated immunoreactivity and nonspecific immunoresistance, reduced length of stay of patients in hospital.

The method of radiation treatment, including chemotherapy, characterized in that patients with leukopenia perform immunotherapy with recombinant interferon-α2b in a daily dose of 3·106ME, which is incubated in thermostat for about 1 h at a temperature of 37°With 100 ml of autologous blood and then injected intravenously drip to the patient within 1-1 .5 hours daily under the control of the blood before reaching the blood content > 4·109/l, granulocytes > 2·109/HP



 

Same patents:

The invention relates to medicine and can be used as a nonspecific test

FIELD: agriculture, veterinary science.

SUBSTANCE: during the 1st d after forming raising groups one should once inject intramuscularly a solution of "Complex A" preparation at the dosage of 0.30-0.32 mg/kg body weight for 45-60-d-aged piglets and simultaneously with fodder one should introduce "Lactobifadol" preparation at the quantity of 0.50-0.52 g/kg body weight during the first 1-5 d. The present innovation enables to activate immune system, increase total protein and hemoglobin in blood that in its turn, prevents bronchopneumonia and remove stress in piglets after forming special raising groups.

EFFECT: higher efficiency of prophylaxis.

1 ex, 1 tbl

FIELD: medicine, ophthalmology.

SUBSTANCE: as an immunomodulating remedy one should introduce tamerite per 0.5 ml subconjunctivally and per 1.5 ml i/m daily for 5 d. The method provides normalization of immunity values due to additional local complex manifestation of immunomodulating, antiphlogistic, antioxidant and regenerating effects of tamerite.

EFFECT: higher efficiency of complex therapy.

2 ex

FIELD: food industry.

SUBSTANCE: invention relates to food additives that can be used to prevent immunodeficiency conditions. Immunomodulator is prepared via homogenization of lymphatic nodes in sodium chloride solution, autolysis, centrifugation, heating of supernatant to 80°C, cooling, removal of precipitate, and drying of supernatant by cooling it and placing it into atmospheric sublimation installation followed by subsequent post-drying using IR drying technique.

EFFECT: simplified immunomodulator preparation process and preserved biological and food values of finished product without creation of special temperature regime.

5 tbl, 2 ex

FIELD: applied immunology.

SUBSTANCE: composition contains, wt parts: borax decahydrate1-25, sodium thiosulfate pentahydrate 10-5-10-4, potassium carbonate 30-150, refined sugar 30-200, and water 100-200 per 100 wt parts of sodium metasilicate pentahydrate. In addition to its capability of improving resistance to diseases, body weight increase, productivity of agricultural plants, quality of crop, and ripening term (harvest time), composition according to invention possesses nonspecific immunostimulating activity, including production of antibodies and enhancement of immunity through activation of immunocytes thereby maximally strengthening vaccination effect regarding diseases caused by malignant neoplasm viruses.

EFFECT: increased assortment of immunostimulating agents.

10 cl, 11 dwg, 12 ex

FIELD: medicine, immunology, veterinary science, pharmacy.

SUBSTANCE: invention concerns a medicinal agent modulating the immune response of body. Agent is made as a tablet covered by envelope. The table core comprises thymus preparation, sodium nucleate, potato starch and the accessory substances taken in the definite ratio of components. As the thymus preparation immunomodulating agent can comprise tactivine or thymaline, or thymogen. The core is covered by envelope comprising acetylphthalylcellulose, castor oil, vaseline oil, titanium dioxide, tropeolin "O" taken in the definite ratio of components. Invention expands assortment of immunomodulating agent by the development of immunomodulating agent that acts on T- and B-lymphocytes simultaneously and on macrophage link of immune system that is suitable in using by children and other patient groups for a long time wherein injection method of administration is not desirable. The immunomodulating agent "Ribotab" elicits high effectiveness providing correction of immunity by tableting agent "Ribotab" after its using in a single dose.

EFFECT: improved and valuable properties of agent.

2 cl, 2 tbl, 5 ex

FIELD: medicine, pediatrics, pulmonology.

SUBSTANCE: in blood serum under testing one should detect the level of specific IgE-AB to S. pneumoniae antigen and at its value being above 0 kU/l it is necessary to perform single vaccination with "Pneumo 23" preparation at the dosage of 0.5 ml intramuscularly regardless of the period of exacerbation at the background of basic therapy. The present innovation enables to increase immunity that in its turn increases efficiency of pharmacotherapy at bronchial asthma and decreases sickness rate at ARVI.

EFFECT: higher efficiency of prophylaxis.

2 ex

Immunomodulator // 2252757

FIELD: immunology.

SUBSTANCE: invention relates to application of 2-Br-phenoxyacetic acid tris-(2-oxiethyl)ammonium salt with antioxidant activity as immunomodulator. Claimed compound gas stimulates action on mieloactivity and original humoral response, which was estimated on the base of amount of lgM-antibody forming cells, as well as depressive action on cell immune response and cell proliferation of spleen. Compound of present invention with immunological properties is useful in production of pharmaceuticals for treatment of various immune pathological conditions.

EFFECT: new application of known antioxidant as immunomodulator.

4 ex, 4 tbl

FIELD: veterinary science.

SUBSTANCE: the suggested methods and compositions provide transfer of biologically active compound, antigen predominantly, in animal body. Efficient quantity of biologically active compound should be put into microcapsules made of biocompatible material the size of which do not exceed 10 mcm, then one should introduce efficient quantity of these microcapsules, perorally, preferably, for animals under immunization. As material for microcapsules one usually applies a biologically active polymer or copolymer being of capacity to pass through gastro-intestinal tract or being localized at mucosal surface not being affected by biodegradation. This provides the transfer of biologically active compound onto Peyer's patches or other mucosa-associated lymphatic tissues, that provides inducing systemic immunity and activization of mucosal immunity system.

EFFECT: higher efficiency.

22 cl, 12 ex, 19 tbl

FIELD: medicine.

SUBSTANCE: method involves taking lavage fluid samples from injured bronchi in preoperative period in making fiber-optic bronchoscopy examination. Microflora colonizing bronchial mucous membrane and its sensitivity to antibiotics is determined. Therapeutic dose of appropriate antibiotic and therapeutic dose of immunomodulator agent like leykinferon is introduced in endolymphatic way 40-60 min before operation. Smears are taken from outlying bronchi in doing operation. Sputum or fluid in retained pleural cavity are taken in 1-2 days after the operation. Prophylaxis effectiveness is determined on basis of bacteriological study data. Therapeutic dose of antibiotics and leykinferon are introduced in 6-8 and 20-24 h after the operation in endolymphatic way. The preparations are introduced at the same doses in endolymphatic way making pauses depending on selected antibiotic elimination half-time once or twice a day until the drains are removed mostly during 48-72 h after operation.

EFFECT: enhanced effectiveness of antibacterial protection; high reliability of antibiotic prophylaxis.

FIELD: organic chemistry, medicine, immunology.

SUBSTANCE: invention proposes applying 2,4-dichlorophenoxyacetic acid tris-(2-oxyethyl)-ammonium salt as an immunomodulating agent. The newly found properties provide the development on its base medicinal agents for treatment of inflammatory, autoimmune and lymphoproliferative diseases.

EFFECT: valuable medicinal properties of agent, expanded assortment of agents of indicated designation.

4 tbl, 4 ex

FIELD: agriculture, veterinary science.

SUBSTANCE: during the 1st d after forming raising groups one should once inject intramuscularly a solution of "Complex A" preparation at the dosage of 0.30-0.32 mg/kg body weight for 45-60-d-aged piglets and simultaneously with fodder one should introduce "Lactobifadol" preparation at the quantity of 0.50-0.52 g/kg body weight during the first 1-5 d. The present innovation enables to activate immune system, increase total protein and hemoglobin in blood that in its turn, prevents bronchopneumonia and remove stress in piglets after forming special raising groups.

EFFECT: higher efficiency of prophylaxis.

1 ex, 1 tbl

FIELD: oncological diseases.

SUBSTANCE: invention is designed for use in complex treatment of urinary bladder cancer in case of propagation of tumor to sub-epithelium connective tissue. Method comprises transurethral resection and introduction of immune preparations and furacillin solution. Once transurethral resection completed, three-way Foli catheter is transurethrally introduced to patient, through which mixture of standard furacillin solution with 10·106 ME interferon α-2β is injected from the first postoperative day and over following 3-5 postoperative days bringing summary dose of interferon to 50·106 ME.

EFFECT: prevented traumatism of urinary bladder due to single introduction of catheter and assured continuous action of drugs without development of immune complications.

FIELD: medicine, immunology.

SUBSTANCE: method involves inhalation administration of combination of immunocorrecting agents wherein recombinant interleukin-2 is used or its combination with genetic engineering α2-interferon and with the complex immunoglobulin preparation in the daily doses for 5 days depending on age of patient. Before sanitation with an immunocorrecting agent the method involves assay of carrying type by anti-lysozyme activity of microorganisms (resident or transitory) and repeated examination after sanitation course is carried out. Carriers are subjected for additional sanitation with anti-bacterial preparations in change of carrying type from resident to transitory and with taking into account antibiotic-resistance property of the carrier strain. Method allows carrying out the effective sanitation and immune reablement of germ carriers due to recovery of the adequate natural resistance and complex of nonspecific factor of regional and systemic immunity.

EFFECT: improved and effective method for sanitation.

2 cl, 2 tbl, 5 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to an agent with broad spectrum of biological effect. Agent based on natural interferon and/or recombinant interferon of α- and/or β- and/or γ-types. Agent is made in the form of different medicinal formulations and elicits immunomodulating, antibacterial, antioxidant and regenerating effect and designated for both internal using and external applying on skin and mucosa tissues. Invention provides the development of medicinal agent with broad spectrum of biological action. The prolonged administration of preparation doesn't effect on morphological composition of peripheral blood and has no effect on blood coagulation. The preparation doesn't show topical irritation and pyrogenic effect.

EFFECT: valuable medicinal properties of agent.

22 cl, 8 ex

FIELD: medicine, obstetrics.

SUBSTANCE: at the first stage of pregravidic training one should introduce leukinferon per 10000 IU intramuscularly every other day 10 times, at the second stage it is necessary to perform 3 seances of discrete plasmapheresis. The present innovation enables to decrease the frequency in developing gestosis and the risk for abortion due to normalized activity of female immune system, that in its turn, enables to stop virusemia and virusuria, prevent fetoplacental failure and intrauterine fetal infectioning.

EFFECT: higher efficiency of training.

3 ex, 1 tbl

FIELD: medicine, anesthesiology-resuscitation, infectology, detoxication.

SUBSTANCE: the innovation suggested interrupts infectious-toxic shock, moreover, after that it is necessary to prescribe peroral intake of Reaferon-EC-Lipint at the dosage of 10000 - 15000 U/kg. Then one should sample patient's blood to obtain leukocytes to be washed and diluted in 0.9%-NaCl solution, activated due to incubation with immunophan and intravenously injected for a patient. Then comes peroral intake of Reaferon-EC-Lipint at the dosage of 10000 - 15000 U/kg once daily for 5 d. The innovation enables to decrease the number of complications and lethality due to decreasing immunodeficiency.

EFFECT: higher efficiency of therapy.

3 ex, 1 tbl

The invention relates to medicine, namely to compositions and methods for potentiating the therapeutic effects of interferon, and can be used for preparation of medicines interferon for use in medicine and veterinary medicine

The invention relates to biotechnology and is intended for use in the pharmaceutical industry for the production of a stable aqueous solution of genetically engineered interferon-alpha-two, not containing albumin for injection for treatment of various viral diseases and cancer

The invention relates to medicine, in particular to the gynecologist, and for the treatment of women suffering from endocrine forms of infertility
Up!